Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Tumor mutational burden • IO biomarker
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler)
|
IDH1 R132
|
Bavencio (avelumab) • IDH1R132H peptide vaccine